Preclinical activity of sacituzumab govitecan in TROP2-positive low-grade serous ovarian cancer patient-derived xenograft models.

By V. Ettorre, Cem Demirkiran, S. Bellone, Na Niu, N. Buza, Namrata Sethi, Tobias Max Philipp Hartwich, Luca Palmieri, Alessandro D. Santin. 2025

Subfields: Cancer Research, Oncology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “These fi ndings reinforce previous observations that TROP2 is broadly expressed across epithelial malignancies (27 – 29) and may represent a stable tumor-associated surface antigen suitable for targeted therapeutic strategies (19, 30 – 32).”